LEMBOREXANT

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H20F2N4O2
Molecular Weight	410.4166
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC=CC(F)=C4)C(C)=N1

InChI

InChIKey=MUGXRYIUWFITCP-PGRDOPGGSA-N

InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H20F2N4O2
Molecular Weight	410.4166
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.eisai.com/news/enews201678pdf.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27338807 | http://adisinsight.springer.com/drugs/800035210

Lemborexant is a dual orexin receptor antagonist, which inhibits orexin by binding competitively to two subtypes of orexin receptors. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully facilitate the initiation and maintenance of sleep by interfering with orexin neurotransmission with lemborexant. Extensive in vitro and non-clinical testing of lemborexant supported the supposition that lemborexant has a low risk of QT prolongation at therapeutic and supratherapeutic exposures in humans. A Phase III study of lemborexant in insomnia is underway, and in addition, Eisai has announced the initiation of Phase II clinical studies of lemborexant in patients with irregular sleep-wake rhythm disorder.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27338807	Inhibitor 8504	6.1 µM [IC50]
Orexin receptor 1 8 Target ID: CHEMBL5113 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28559480	Antagonist 2849	6.1 nM [IC50]
Orexin receptor 2 10 Target ID: CHEMBL4792 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28559480	Antagonist 2849	2.6 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 111 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27338807 https://clinicaltrials.gov/ct2/show/NCT02783729 http://adisinsight.springer.com/drugs/800035210	Primary		Phase III 665	Unknown Approved Use Unknown
Irregular sleep-wake rhythm disorder 1 Sources: http://www.eisai.com/news/enews201678pdf.pdf	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
22.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32468649/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
22 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32468649/	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
203 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27338807	25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
146 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32468649/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
169 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32468649/	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
33.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32468649/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32468649/	5 mg 1 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEMBOREXANT plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
17 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	LEMBOREXANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
6% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		LEMBOREXANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	Disc. AE: Somnolence, Nightmares... AEs leading to discontinuation/dose reduction: Somnolence (2.9%) Nightmares (1.3%) Palpitations (0.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	Disc. AE: Somnolence, Nightmares... AEs leading to discontinuation/dose reduction: Somnolence (1%) Nightmares (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/32468649/	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/32468649/	Other AEs: Sleep paralysis... Other AEs: Sleep paralysis (moderate, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/32468649/
75 mg 1 times / day multiple, oral Highest studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649	Other AEs: Headache, Sleep paralysis... Other AEs: Headache (1 patient) Sleep paralysis (1 patient) Insomnia (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649

AEs

AE	Significance	Dose	Population
Palpitations	0.6% Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
Nightmares	1.3% Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
Somnolence	2.9% Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
Nightmares	0.3% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
Somnolence	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	unhealthy, 55 years (range: 18 - 88 years) Health Status: unhealthy Age Group: 55 years (range: 18 - 88 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
Sleep paralysis	moderate, 1 patient	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/32468649/	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/32468649/
Headache	1 patient	75 mg 1 times / day multiple, oral Highest studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649
Insomnia	1 patient	75 mg 1 times / day multiple, oral Highest studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649
Sleep paralysis	1 patient	75 mg 1 times / day multiple, oral Highest studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf https://pubmed.ncbi.nlm.nih.gov/32468649

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 227 P-gp 1741 BCRP 910 BSEP 550 OAT1 725 OAT3 747 OATP1B1 1079 OATP1B3 961 OCT1 620 OCT2 779 MATE1 415 MATE2 267 CYP2A6 879 CYP2C19 2057	CYP3A5 446 P-gp 2052 BCRP 697 OATP1B1 503 OATP1B3 435	CYP3A 142 CYP2B6 669 CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Metabolite
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	no	M10 1
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	no	M4 4
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	no	M9 2
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no	M10 1
CYP3A 317	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	weak	M10 1
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes [IC50 24.6 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes [IC50 7.8 uM]
CYP3A 317	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes [Ki 25.2 uM]
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	yes
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	yes	M10 1
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes	M4 4
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes	M9 2
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	yes
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	yes	M10 1
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes	M4 4
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes	M9 2

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=47 Page: 47.0	major		yes (co-administration study) Comment: The effect of fluconazole (a moderate CYP3A inhibitor) on the PK of lemborexant was evaluated in Study 012 The lemborexant Cmax, AUC0-t and AUC0-inf values increased by approximately 1.6-, 3.8 and 4.2-fold, respectively, as compared with lemborexant alone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=47 Page: 47.0
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=47 Page: 47.0	minor		yes (co-administration study) Comment: The effect of fluconazole (a moderate CYP3A inhibitor) on the PK of lemborexant was evaluated in Study 012 The lemborexant Cmax, AUC0-t and AUC0-inf values increased by approximately 1.6-, 3.8 and 4.2-fold, respectively, as compared with lemborexant alone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=47 Page: 47.0
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	no	M10 1
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=93 Page: 93.0	poor
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=100 Page: 100.0	yes	M10 1

Tox targets

Target	Modality	Metabolite
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=46 Page: 46.0
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=46 Page: 46.0	M10 1
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=46 Page: 46.0	M4 1
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf#page=46 Page: 46.0	M9 1

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA0012JH	https://www.aablocks.com/goods/Goods/detail?id=AA0012JH
AbMole Bioscience	M9839	http://www.abmole.com/products/lemborexant.html
Ark Pharma Scientific Limited	A-1745	http://www.arkpharmtech.com/product/33696.html
Chem Scene	CS-4320	http://www.chemscene.com/1369764-02-2.html
Chemspace	CSSB00102527162	https://chem-space.com/CSSB00102527162
DC Chemicals	DC8173	http://www.dcchemicals.com/product_show-Lemborexant_E2006_.html
eNovation Chemicals	D567191	https://www.enovationchem.com/ProductDetails.asp?ProductID=D567191
eNovation Chemicals	Y0975941	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975941
Excenen	EX-A2337	https://www.excenen.com/searchresultlist.php?id=1369764-02-2
Hairui	LECQ022	http://www.hairuichem.com/en/product/1369764-02-2.html
Lab Network	LN01342425	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342425
MedChem Express	HY-16725	https://www.medchemexpress.com/Lemborexant.html
Smolecule	S532739	http://www.smolecule.com/products/s532739
Synblock Inc	SB17434	http://www.synblock.com/product/1369764-02-2.html
THE BioTek	bt-272970	https://www.thebiotek.com/product/inhibitors/bt-272970

PubMed

Title	Date	PubMed
In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.	2017-08	28559480
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.	2017-01	27338807

Patents

Sample Use Guides

In Vivo Use Guide

5 mg or 10 mg before the time the participant intends to try to sleep

Route of Administration: Oral

In Vitro Use Guide

The effect of lemborexant on the slow component of delayed rectifier potassium current (IKs) was examined using KCNQ1/KCNE1-CHO cells and a small, not-concentration-dependent inhibition was noted with a peak inhibitory effect of 24% at 10 (uM, and a smaller effect (13%) at 30 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:35:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:35:46 GMT 2025`
Record UNII	0K5743G68X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

lemborexant [INN]

Preferred Name

English

LEMBOREXANT

Official Name

English

LEMBOREXANT [JAN]

Common Name

English

DAYVIGO

Brand Name

English

(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide

Systematic Name

English

(1R,2S)-2-((2,4-DIMETHYLPYRIMIDIN-5-YL)OXYMETHYL)-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL)CYCLOPROPANE-1-CARBOXAMIDE

Systematic Name

English

LEMBOREXANT [ORANGE BOOK]

Common Name

English

Lemborexant [WHO-DD]

Common Name

English

CYCLOPROPANECARBOXAMIDE, 2-(((2,4-DIMETHYL-5-PYRIMIDINYL)OXY)METHYL)-2-(3-FLUOROPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-, (1R,2S)-

Systematic Name

English

LEMBOREXANT [MI]

Common Name

English

E2006

Code

English

E-2006

Code

English

LEMBOREXANT [USAN]

Common Name

English

Classification Tree Code System Code

DEA NO.

2245